BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37116912)

  • 1. Staging Prostate Cancer with
    Kesler M; Cohen D; Levine C; Sarid D; Keizman D; Yossepowitch O; Even-Sapir E
    J Nucl Med; 2023 Jul; 64(7):1030-1035. PubMed ID: 37116912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of metastatic disease on
    Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
    BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental Impact of [
    Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
    Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How accurate is
    Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
    Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR
    Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
    Kuten J; Mabjeesh NJ; Lerman H; Levine C; Barnes S; Even-Sapir E
    Isr Med Assoc J; 2019 Feb; 21(2):100-104. PubMed ID: 30772960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total-Body
    Pomykala KL; Czernin J; Grogan TR; Armstrong WR; Williams J; Calais J
    J Nucl Med; 2020 Mar; 61(3):405-411. PubMed ID: 31541035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective intra-individual comparison of [
    Lawal IO; Mokoala KMG; Mahapane J; Kleyhans J; Meckel M; Vorster M; Ebenhan T; Rösch F; Sathekge MM
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):134-142. PubMed ID: 32424485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Impact of
    Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
    J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
    Raju S; Sharma A; Patel C; Sahoo R; Das CJ; Kumar S; Sharma A; Kumar R
    Nucl Med Commun; 2020 Nov; 41(11):1183-1188. PubMed ID: 32796451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [
    Hirmas N; Al-Ibraheem A; Herrmann K; Alsharif A; Muhsin H; Khader J; Al-Daghmin A; Salah S
    Mol Imaging Biol; 2019 Jun; 21(3):574-581. PubMed ID: 30215174
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Hamed MAG; Basha MAA; Ahmed H; Obaya AA; Afifi AHM; Abdelbary EH
    Acad Radiol; 2019 Apr; 26(4):450-460. PubMed ID: 29935970
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
    J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer.
    Meyrick DP; Asokendaran M; Skelly LA; Lenzo NP; Henderson A
    Nucl Med Commun; 2017 Nov; 38(11):956-963. PubMed ID: 28922335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of histopathological and biochemical parameters for predicting metastatic disease on
    Aydos U; Çetin S; Akdemir ÜÖ; Budak FÇ; Ateş SG; Koparal MY; Gönül İI; Gülbahar Ö; Sözen S; Atay LÖ
    Prostate; 2021 Dec; 81(16):1337-1348. PubMed ID: 34516677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer.
    Tulsyan S; Das CJ; Tripathi M; Seth A; Kumar R; Bal C
    Nucl Med Commun; 2017 Dec; 38(12):1094-1102. PubMed ID: 28957842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.